Clinical Trial Update: Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial (currently recruiting) evaluating annual versus biannual infusions of ocrelizumab in patients with active multiple sclerosis to asses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Conditions: Multiple Sclerosis | Phase 3 | Status: RECRUITING